Insider Trading History of Efficacy Biotech Master Fund Ltd.

The following table details the insider trading activities (stock purchases, stock sales, and stock option exercises) by Efficacy Biotech Master Fund Ltd. since 2007. The trader's CIK number is 1366070. At the time of the last reporting, Efficacy Biotech Master Fund Ltd. was the 10% Owner of Aeolus Pharmaceuticals, Inc.. (stock ticker symbol AOLS). Also see all insider trading activities at Aeolus Pharmaceuticals, Inc..

Note that in the past Efficacy Biotech Master Fund Ltd. also reported insider trading activities as an insider of the following companies:

Yearly summary of insider trading at Zonagen Inc (RPRX) by Efficacy Biotech Master Fund Ltd.

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2009 RPRX 0 $0 542,903 $369,898 0 $0
2008 RPRX 2,331,688 $15,950,721 302,057 $2,783,355 0 $0
2007 RPRX 783,500 $7,784,855 0 $0 0 $0

Yearly summary of insider trading at Aeolus Pharmaceuticals, Inc. (AOLS) by Efficacy Biotech Master Fund Ltd.

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2011 AOLS 0 $0 4,057,214 $2,527,000 0 $0


Insider trading activities at 2 companies by Efficacy Biotech Master Fund Ltd.:

1. Zonagen Inc (RPRX)

2. Aeolus Pharmaceuticals, Inc. (AOLS)

Table 1. Insider trading of Zonagen Inc (RPRX) by Efficacy Biotech Master Fund Ltd.

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2009-12-21 RPRX Sale 76,703 .65 50,163
2009-12-18 RPRX Sale 30,000 .68 20,280
2009-12-17 RPRX Sale 50,100 .70 35,220
2009-12-11 RPRX Sale 126,500 .70 88,044
2009-12-14 RPRX Sale 77,900 .70 54,452
2009-12-15 RPRX Sale 181,700 .67 121,739
2008-10-24 RPRX Buy 30,000 6.89 206,700
2008-10-23 RPRX Buy 17,309 6.32 109,392
2008-10-27 RPRX Buy 14,825 6.85 101,551
2008-10-17 RPRX Buy 30,000 6.42 192,600
2008-10-17 RPRX Buy 30,000 6.42 192,600
2008-10-10 RPRX Buy 15,300 6.23 95,319
2008-10-13 RPRX Buy 15,000 6.82 102,300
2008-10-02 RPRX Buy 1,846,154 6.50 12,000,001
2008-03-18 RPRX Sale 10,600 8.90 94,340
2008-03-17 RPRX Sale 55,357 8.54 472,748
2008-03-27 RPRX Sale 55,800 9.55 532,890
2008-03-26 RPRX Sale 10,000 9.82 98,200
2008-03-14 RPRX Sale 26,300 8.59 225,917
2008-03-24 RPRX Sale 50,000 9.61 480,500
2008-03-20 RPRX Sale 34,000 8.94 303,960
2008-03-25 RPRX Sale 60,000 9.58 574,800
2008-03-12 RPRX Buy 50,000 8.50 425,000
2008-03-10 RPRX Buy 40,000 8.46 338,400
2008-03-07 RPRX Buy 34,500 8.63 297,735
2008-02-28 RPRX Buy 20,000 8.35 167,000
2008-02-29 RPRX Buy 30,000 8.27 248,100
2008-01-04 RPRX Buy 15,000 8.96 134,400
2008-01-07 RPRX Buy 19,500 9.08 177,060
2007-12-31 RPRX Buy 54,100 9.43 510,163
2007-12-28 RPRX Buy 70,000 9.32 652,400
2007-12-20 RPRX Buy 60,000 9.49 569,400
2007-12-21 RPRX Buy 40,000 9.38 375,200
2007-12-19 RPRX Buy 43,500 9.84 428,040
2007-12-18 RPRX Buy 42,100 9.79 412,158
2007-12-13 RPRX Buy 40,100 8.70 348,870
2007-12-14 RPRX Buy 120,000 9.78 1,173,600
2007-12-05 RPRX Buy 39,300 8.18 321,474
2007-12-06 RPRX Buy 60,000 7.96 477,600
2007-12-03 RPRX Buy 71,500 7.86 561,990
2007-12-04 RPRX Buy 50,000 8.35 417,500
2007-10-22 RPRX Buy 25,000 12.18 304,550
2007-10-19 RPRX Buy 40,500 12.34 499,608
2007-10-18 RPRX Buy 21,900 12.48 273,333
2007-10-17 RPRX Buy 62,600 12.44 778,744
2007-10-25 RPRX Buy 17,000 12.69 215,713
2007-10-23 RPRX Buy 25,000 12.53 313,350
2007-10-24 RPRX Buy 25,000 12.55 313,725

Table 2. Insider trading of Aeolus Pharmaceuticals, Inc. (AOLS) by Efficacy Biotech Master Fund Ltd.

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2011-03-15 AOLS Sale 193,234 .76 146,857
2011-03-16 AOLS Sale 3,799,380 .61 2,317,621
2011-02-15 AOLS Sale 7,000 .95 6,650
2011-02-16 AOLS Sale 57,600 .97 55,872

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Efficacy Biotech Master Fund Ltd. (10% Owner of Aeolus Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.